{
  "meta": {
    "title": "Immunology_Vaccines",
    "url": "https://brainandscalpel.vercel.app/immunology-vaccines-d743cccf.html",
    "scrapedAt": "2025-11-30T11:19:26.869Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">X-linked agammaglobulinemia</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Chediak-Higashi syndrome</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Terminal complement C5b-C9 deficiency</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Human immunodeficiency virus infection</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A previously healthy 9-year-old child is admitted for the second episode of meningococcemia within a year. Past medical history is unremarkable except for the prior hospitalization. Laboratory investigations confirm Neisseria meningitidis in blood culture. Which of the following immunodeficiency states most likely explains this recurrent infection?</span></p>",
      "unique_key": "DT1325168",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325168,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Recurrent infections with <strong>encapsulated Neisseria species</strong> (especially <strong>Neisseria meningitidis</strong>) strongly suggest a defect in the <strong>terminal complement pathway</strong>:</p>\r\n<ul>\r\n<li>The <strong>membrane attack complex (MAC)</strong> is formed by <strong>C5b to C9 components</strong> of the complement cascade.</li>\r\n<li>MAC plays a <strong>critical role in lysing gram-negative bacteria</strong>, especially <strong>Neisseria</strong>.</li>\r\n<li>Patients with <strong>C5-C9 deficiency</strong> are typically healthy otherwise but present with <strong>recurrent meningococcal infections</strong>-a classic diagnostic clue.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>X-linked agammaglobulinemia (Option A): </strong>Causes <strong>severe B-cell deficiency</strong>, leading to early-onset sinopulmonary and GI infections not isolated Neisseria infections. Typically presents before age 2 with <strong>absent tonsils and lymph nodes</strong>.</p>\r\n<p><strong>Chediak-Higashi syndrome (Option B): </strong>A rare phagocytic disorder with <strong>partial albinism, giant granules in neutrophils</strong>, and recurrent <strong>staph/streptococcal</strong> infections not Neisseria.</p>\r\n<p><strong>HIV infection (Option D): </strong>Affects <strong>T-cell mediated immunity:</strong> leads to susceptibility to <strong>fungal, viral, and opportunistic infections</strong> not typically recurrent Neisseria.</p>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<p><strong>Recurrent meningococcal infections in an otherwise healthy child are highly suggestive of terminal complement (C5-C9) deficiency</strong>, due to failure of membrane attack complex formation.</p>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Severe Microcephaly</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Polydactyly</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Seizures</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Recurrent Candidiasis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An infant had refractory hypocalcemia in the first few weeks of life and was diagnosed with congenital hypoparathyroidism. The child was referred to a pediatric cardiologist for further evaluation since a heart disease was suspected. The child also has abnormal facies and cleft palate. Which other clinical manifestation will often be present in such a child?</span></p>",
      "unique_key": "DT1230034",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230034,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This clinical picture is typical of <strong>22q11.2 deletion syndrome (DiGeorge Syndrome)</strong>, which results from defective development of the <strong>third and fourth pharyngeal pouches</strong>.</p>\n<ul>\n<li>Key features include:\n<ul>\n<li><strong>Congenital hypoparathyroidism</strong> &rarr; hypocalcemia</li>\n<li><strong>Congenital heart disease</strong> (commonly conotruncal anomalies)</li>\n<li><strong>Abnormal facies</strong>, cleft palate, bifid uvula</li>\n<li><strong>Thymic hypoplasia</strong> &rarr; <strong>T-cell immunodeficiency</strong></li>\n</ul>\n</li>\n<li>This <strong>T-cell deficiency</strong> leads to <strong>recurrent infections</strong>, especially <strong>viral and fungal</strong>.</li>\n<li><strong>Recurrent mucocutaneous candidiasis</strong> is common in early infancy.</li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<ul>\n<li>The syndrome may present with <strong>seizures</strong> due to hypocalcemia, but <strong>fungal infections</strong> like candidiasis are more specific to the immunodeficiency.</li>\n<li>Diagnosis is confirmed by <strong>FISH or microarray</strong> showing 22q11.2 deletion.</li>\n<li>Management includes <strong>calcium supplementation</strong>, monitoring for infections, and cardiac defect correction.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Severe Microcephaly (Option A):</strong> Not associated with DiGeorge; seen in congenital infections or syndromes like Zika.</p>\n<p><strong>Polydactyly (Option B):</strong> Seen in syndromes like Ellis-van Creveld, not DiGeorge.</p>\n<p><strong>Seizures (Option C):</strong> Can occur due to hypocalcemia but are a <strong>complication</strong>, not a hallmark feature.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Recurrent candidiasis in a neonate with hypocalcemia, cleft palate, and cardiac anomalies points toward <strong>22q11.2 deletion syndrome</strong> with T-cell immunodeficiency.</p>",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">A</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">B</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">C</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A child was born with the absence of the thymus gland and congenital hypoparathyroidism. This is likely to be due to maldevelopment of which of the following structures in the labelled branchial arch structure below?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240319da1cf4b2-d30b-4a7d-b7b2-27a2c3b72670.jpg\"></span></p>",
      "unique_key": "DT1230087",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230087,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Absence of the thymus gland and hypoparathyroidism due to branchial arch defect likely suggests a diagnosis of DiGeorge Syndrome, which arises due to 3<sup>rd</sup> and sometimes 4<sup>th</sup> pharyngeal pouch hypoplasia. Option C indicates the 3<sup>rd</sup> pharyngeal pouch and is thus the likely answer here.</p>\n<ul>\n<li>The cause of DiGeorge Syndrome is microdeletions in the Chromosome 22q11.2 region</li>\n<li>It can be sporadic or inherited. Inherited forms show Autosomal Dominant inheritance</li>\n</ul>\n<p><strong>Clinical features can be remembered by the mnemonic: CATCH- 22</strong></p>\n<ul>\n<li>C- Cardiac defects(Interrupted aortic arch syndrome &gt; truncus arteriosus &gt; TOF)</li>\n<li>A- Abnormal facies</li>\n<li>T- Thymic hypoplasia &rarr; T cell defects</li>\n<li>C- Cleft palate (may/may not be present in all cases)</li>\n<li>H- Hypocalcaemia - due to PTH gland hypoplasia</li>\n<li>22- Chromosome Involved</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>(A) A:</strong> Likely refers to 1st pouch &rarr; forms auditory tube and middle ear structures not involved in thymus or parathyroid formation</p>\n<p><strong>(B) B:</strong> Likely refers to 2nd pouch &rarr; forms palatine tonsils</p>\n<p><strong>(D) D:</strong> Likely refers to 5th pouch (if present) or ultimobranchial body &rarr; contributes to parafollicular (C) cells of the thyroid</p>\n<p><strong>Key Takeaway:</strong></p>\n<p><strong>DiGeorge syndrome</strong> results from defective development of the <strong>3rd (and 4th) pharyngeal pouches</strong>, affecting <strong>thymus and parathyroid glands</strong>.</p>",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyper IgE Syndrome</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyper IgM Syndrome</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">IgG2 subclass deficiency</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Selective IgA deficiency</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 9-month-old male infant presents with a history of recurrent pneumonia, otitis media, and chronic diarrhea. Laboratory testing shows markedly elevated serum IgM levels with undetectable IgG and IgA. Genetic testing reveals a defect in the CD40 ligand gene. Which of the following immunodeficiency disorders is most likely in this child?</span></p>",
      "unique_key": "DT1230057",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230057,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Hyper IgM Syndrome (HIGM)</strong> is a rare <strong>primary immunodeficiency disorder</strong> characterized by a defect in <strong>class-switch recombination (CSR)</strong>, usually due to <strong>CD40L gene mutation (X-linked form)</strong>.</p>\n<ul>\n<li><strong>Mechanism:</strong> Failure of B cells to switch from IgM to other isotypes (IgG, IgA, IgE) despite normal or increased IgM production.</li>\n<li><strong>Clinical features:</strong>\n<ul>\n<li>Recurrent <strong>bacterial and opportunistic infections</strong> (e.g., Pneumocystis jirovecii pneumonia)</li>\n<li><strong>Chronic diarrhea</strong>, failure to thrive</li>\n<li><strong>Severe neutropenia</strong> in some cases</li>\n</ul>\n</li>\n<li><strong>Immunoglobulin profile:</strong>\n<ul>\n<li><strong>Elevated or normal IgM</strong></li>\n<li><strong>Absent or very low IgG, IgA, and IgE</strong></li>\n</ul>\n</li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<ul>\n<li>Most common genetic form is <strong>X-linked</strong>, due to mutation in <strong>CD40 ligand</strong> on activated T-helper cells.</li>\n<li>Other causes include <strong>CD40</strong> or <strong>AID gene</strong> mutations (autosomal recessive).</li>\n<li>Treatment includes <strong>IVIG replacement</strong> and <strong>hematopoietic stem cell transplant</strong> for definitive cure.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Hyper IgE Syndrome (Option A):</strong> Characterized by high IgE, eosinophilia, eczema, and cold abscesses not a CSR defect.</p>\n<p><strong>IgG2 subclass deficiency (Option C):</strong> Affects specific IgG subclass; class switching is intact.</p>\n<p><strong>Selective IgA deficiency (Option D):</strong> Normal IgG and IgM; only IgA is low CSR is not defective.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p><strong>Hyper IgM Syndrome</strong> results from defective <strong>class-switch recombination</strong>, leading to elevated IgM and low IgG, IgA, IgE levels-causing combined humoral and cellular immunodeficiency.</p>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-platelet antibody assessment</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Screening for WASp expression</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Bone marrow aspiration</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Liver and renal function tests</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 2-year-old boy presents with recurrent episodes of bloody diarrhea, a pruritic eczematous rash over the face and flexures, and a history of easy bruising. On evaluation, CBC reveals a normal total leukocyte count and platelet count of 20,000/mm<sup>3</sup>. What is the next best investigation to confirm the most likely diagnosis?</span></p>",
      "unique_key": "DT1230063",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230063,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This child presents with the <strong>classic triad</strong> of <strong>Wiskott-Aldrich Syndrome (WAS)</strong>:</p>\n<ul>\n<li><strong>Eczema</strong> (atopic dermatitis-like rash)</li>\n<li><strong>Recurrent infections</strong> (bloody diarrhea from enteric pathogens)</li>\n<li><strong>Thrombocytopenia with small-sized platelets</strong> (manifesting as petechiae or bleeding)</li>\n</ul>\n<p>WAS is an <strong>X-linked recessive primary immunodeficiency</strong> caused by <strong>mutations in the WAS gene</strong> (located on <strong>X chromosome at Xp11.23</strong>) leading to defective <strong>WAS protein (WASp)</strong> expression in hematopoietic cells.</p>\n<ul>\n<li><strong>Screening for WASp expression via flow cytometry</strong> or <strong>genetic testing</strong> is the best next diagnostic step.</li>\n<li>Early diagnosis is crucial as <strong>hematopoietic stem cell transplant (HSCT)</strong> is the definitive treatment.</li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<ul>\n<li>Platelets in WAS are <strong>low in number and small in size</strong>, unlike large platelets in ITP.</li>\n<li>These children are at increased risk for <strong>autoimmune disease</strong> and <strong>malignancy</strong>.</li>\n<li>Supportive care includes <strong>IVIG</strong>, <strong>platelet transfusions</strong>, and <strong>antibiotic prophylaxis</strong> until HSCT.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Anti-platelet antibody assessment (Option A):</strong> Useful in <strong>ITP</strong>, not in syndromic thrombocytopenia with immunodeficiency.</p>\n<p><strong>Bone marrow aspiration (Option C):</strong> Indicated in <strong>pancytopenia or leukemia suspicion</strong>, not needed initially here.</p>\n<p><strong>LFT and RFT (Option D):</strong> Irrelevant to the diagnostic work-up of immunodeficiency or thrombocytopenia.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>A child with <strong>eczema, recurrent infections, and thrombocytopenia</strong> should be evaluated for <strong>Wiskott-Aldrich Syndrome</strong> via <strong>WASp expression testing</strong>.</p>",
      "correct_choice_id": 42,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">It is inherited as an autosomal dominant disorder</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">It is associated with micro thrombocytopenia, eczema and immunodeficiency</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Intrinsic abnormalities of B-cell function are a common feature</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Low levels of IgM and increased levels of IgA, IgD and IgE can be found</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The following are true with regard to Wiskott-Aldrich syndrome except?</span></p>",
      "unique_key": "DT1230074",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230074,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Wiskott-Aldrich Syndrome (WAS)</strong> is a rare primary immunodeficiency disorder characterized by a classic clinical triad and progressive immune dysfunction. It is caused by mutations in the WAS gene.</p>\n<h4>Pathophysiology:</h4>\n<ul>\n<li>The disorder is inherited in an X-linked recessive manner, primarily affecting males.</li>\n<li>Mutations in the WAS gene (Xp11.23) result in defective expression of WASp protein, which plays a key role in actin cytoskeleton remodeling in hematopoietic cells.</li>\n<li>This leads to combined T-cell and B-cell dysfunction, abnormal platelet production, and immune dysregulation.</li>\n</ul>\n<h4>Classic Triad of WAS: (Option B)</h4>\n<ol>\n<li>Eczema (atopic dermatitis-like rash)</li>\n<li>Microthrombocytopenia (low platelet count with small-sized platelets)</li>\n<li>Recurrent infections (due to both humoral and cellular immune deficiency)</li>\n</ol>\n<h4>Laboratory Features:</h4>\n<ul>\n<li>Immunoglobulin profile:\n<ul>\n<li>&darr; IgM, &uarr; IgA, IgE, and often IgD <strong>(Option D)</strong></li>\n</ul>\n</li>\n<li>B-cell defect: Poor antibody response to polysaccharide antigens <strong>(Option C)</strong></li>\n<li>T-cell defect: Progressive T-cell depletion, impaired delayed-type hypersensitivity (DTH)</li>\n<li>CBC &amp; peripheral smear: Thrombocytopenia with small-sized platelets</li>\n</ul>\n<h4>Confirmatory Tests:</h4>\n<ul>\n<li>Flow cytometry for WASp expression</li>\n<li>Molecular genetic testing for WAS gene mutation</li>\n</ul>\n<p><strong>Key Takeaway:</strong></p>\n<p>Wiskott-Aldrich Syndrome is an X-linked recessive disorder presenting with eczema, thrombocytopenia, and immunodeficiency. Defective WASp protein leads to both T and B cell dysfunction.</p>",
      "correct_choice_id": 51,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum levels of IgG, IgM, IgA, IgE</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">A complete blood count with differential</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Peripheral T-cell phenotyping</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Erythrocyte sedimentation rate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 6-month-old infant presents with recurrent otitis media, persistent diarrhea, and poor weight gain. Immunodeficiency is suspected. Which of the following investigations is the best initial screening test in the evaluation of this child?</span></p>",
      "unique_key": "DT1230069",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230069,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>In evaluating a suspected <strong>primary immunodeficiency</strong>, the <strong>first and most informative screening test</strong> is a <strong>complete blood count (CBC) with differential</strong>, because it can:</p>\n<ul>\n<li>Detect <strong>lymphopenia</strong> &rarr; suggests <strong>T-cell or combined immunodeficiency</strong></li>\n<li>Detect <strong>neutropenia</strong> &rarr; suggests <strong>phagocytic disorders or congenital neutropenia</strong></li>\n<li>Show <strong>eosinophilia</strong> &rarr; may point toward <strong>hyper-IgE syndrome or parasitic infections</strong></li>\n<li>Reveal <strong>thrombocytopenia with small platelets</strong> &rarr; characteristic of <strong>Wiskott-Aldrich syndrome</strong></li>\n</ul>\n<p>Although serum immunoglobulins and lymphocyte subset analysis are important, they are <strong>second-line investigations</strong> after a basic hematological screen.</p>\n<p><strong>Related Important Points:</strong></p>\n<ul>\n<li>Initial evaluation should always begin with <strong>CBC + peripheral smear</strong>.</li>\n<li><strong>Serum Ig levels</strong> are helpful but may be age-dependent and may not detect cellular defects.</li>\n<li><strong>T-cell phenotyping</strong> (CD3/CD4/CD8) and functional antibody responses are reserved for <strong>second-line</strong> workup.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Serum Ig levels (Option A):</strong> Useful for antibody deficiencies but <strong>not first-line</strong>; age-related variation may confuse interpretation.</p>\n<p><strong>Peripheral T-cell phenotyping (Option C):</strong> Valuable for SCID and combined deficiencies, but requires specialized flow cytometry.</p>\n<p><strong>ESR (Option D):</strong> Nonspecific inflammatory marker; <strong>not useful in diagnosing immunodeficiency</strong>.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p><strong>CBC with differential</strong> is the <strong>first-line screening test</strong> in the workup of suspected immunodeficiency, as it provides vital clues about lymphocytes, neutrophils, and platelets.</p>",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Failure to thrive</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Pneumonitis</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Eczema</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Recurrent thrush</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The presentation of a child with severe combined immune deficiency can be as all of the following except?</span></p>",
      "unique_key": "DT1230198",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230198,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Severe Combined Immunodeficiency (SCID) represents a group of rare, life-threatening primary immunodeficiencies characterized by:</p>\n<ul>\n<li>Profound defects in both T-cell and B-cell function, and sometimes NK cells</li>\n<li>Caused by mutations in genes such as:\n<ul>\n<li>IL2RG (X-linked SCID)</li>\n<li>JAK3, ADA, RAG1/2, etc.</li>\n</ul>\n</li>\n<li>Leads to absence or dysfunction of lymphocytes, resulting in:\n<ul>\n<li>Impaired cellular immunity (defective T cells)</li>\n<li>Impaired humoral immunity (non-functional B cells due to lack of T-cell help)</li>\n</ul>\n</li>\n</ul>\n<p>This results in early-onset, severe infections by bacteria, viruses, fungi, and protozoa, typically beginning within the first 3 months of life.</p>\n<p><strong>Clinical Features of SCID:</strong></p>\n<ul>\n<li>Failure to thrive</li>\n<li>Chronic diarrhea</li>\n<li>Recurrent thrush (oral candidiasis)</li>\n<li>Severe pneumonitis (e.g., <em>Pneumocystis jirovecii</em>, RSV, CMV)</li>\n<li>No palpable lymph nodes or tonsils (due to lymphoid hypoplasia)</li>\n<li>Disseminated BCG disease if vaccinated at birth</li>\n</ul>\n<p>Eczema is not a typical manifestation of SCID. If present, it may suggest alternate diagnoses such as Wiskott-Aldrich Syndrome or Hyper-IgE Syndrome.</p>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Failure to thrive (Option A):</strong> Very common due to energy loss from chronic infection and malabsorption</p>\n<p><strong>Pneumonitis (Option B): </strong>Often the presenting feature due to opportunistic infections (e.g., <em>P. jirovecii</em>)</p>\n<p><strong>Recurrent thrush (Option D): </strong>Suggests underlying T-cell immunodeficiency and is frequently seen in SCID</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>SCID presents with severe infections, lymphoid hypoplasia, and failure to thrive. Eczema is not characteristic and should raise suspicion for other combined immunodeficiencies.</p>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic granulomatous disease</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Chediak-Higashi syndrome</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Leukocyte adhesion deficiency</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Purine nucleoside phosphorylase deficiency</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 2-year-old boy presents with recurrent urinary tract infections and chest infections. His mother reports that umbilical cord separation occurred at 3 weeks of age. He previously required IV antibiotics and plastic surgery for a serious skin infection. Laboratory tests show abnormal neutrophil adhesion, chemotaxis, and phagocytosis, while antibody levels and vaccine responses are normal. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1230077",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230077,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The child presents with hallmark features of Leukocyte Adhesion Deficiency (LAD):</p>\n<ul>\n<li>Delayed umbilical cord separation (&gt;2 weeks)</li>\n<li>Recurrent bacterial infections of skin, respiratory tract, and mucosa</li>\n<li>Impaired neutrophil function specifically adhesion, chemotaxis, and transmigration</li>\n<li>Normal lymphocyte numbers and antibody responses</li>\n</ul>\n<p><strong>Pathophysiology:</strong></p>\n<ul>\n<li>LAD is usually caused by a CD18 (&beta;2 integrin) deficiency (LAD Type I).</li>\n<li>As phagocytes cannot adhere to endothelium, they fail to migrate to infection sites &rarr; leading to severe, localized but non-purulent infections.</li>\n<li>Inheritance is autosomal recessive.</li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<ul>\n<li>Marked leukocytosis (&gt;30,000/mm&sup3;) is common.</li>\n<li>Lymphocyte functions using LFA-1 (in the CD2 pathway) are impaired.</li>\n<li>Definitive treatment: Allogeneic hematopoietic stem cell transplant (HSCT)</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Chronic granulomatous disease (Option A): </strong>Normal neutrophil adhesion but defective oxidative burst. Presents with abscesses and catalase-positive organisms.</p>\n<p><strong>Chediak-Higashi syndrome (Option B):</strong> Characterized by albinism, giant granules in neutrophils, and neurologic defects.</p>\n<p><strong>Purine nucleoside phosphorylase deficiency (Option D): </strong>Causes T-cell immunodeficiency, but not associated with delayed cord separation or neutrophil adhesion defect.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Delayed cord separation, severe localized infections, and defective neutrophil adhesion point toward Leukocyte Adhesion Deficiency (LAD).</p>",
      "correct_choice_id": 83,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Chediak-Higashi Syndrome</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic Granulomatous Disease</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Ataxia Telangiectasia</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Leukocyte Adhesion Defects</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All of the following are phagocytic disorders except?</span></p>",
      "unique_key": "DT1230090",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230090,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Primary immunodeficiency disorders are broadly classified based on the immune compartment affected: B cells, T cells, combined B and T cells, phagocytes, and complement.</strong></p>\n<ul>\n<li><strong>Ataxia Telangiectasia (AT) is a combined immunodeficiency, with both B-cell and T-cell dysfunction, along with cerebellar ataxia and oculocutaneous telangiectasias.<br /> </strong></li>\n<li><strong>It is not a phagocytic disorder.<br /> </strong></li>\n</ul>\n<p><strong>In contrast, the other options represent classic phagocytic disorders:</strong></p>\n<ul>\n<li><strong>Chediak-Higashi Syndrome (CHS): </strong>Defect in lysosomal trafficking regulator &rarr; impaired neutrophil degranulation <strong>(Option A ruled out)</strong></li>\n<li><strong>Chronic Granulomatous Disease (CGD): </strong>NADPH oxidase defect &rarr; impaired respiratory burst<strong> (Option B ruled out)</strong></li>\n<li><strong>Leukocyte Adhesion Deficiency (LAD):</strong> CD18 or selectin ligand defect &rarr; defective neutrophil adhesion and migration<strong> (Option D ruled out)</strong></li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509070cb68f65-65fd-407c-a74e-200ad0072e43.png\">\n<p><strong>Key Takeaway:</strong></p>\n<p>Ataxia Telangiectasia is a combined B and T cell immunodeficiency, not a phagocytic disorder.</p>",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">LYST</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">NCFI</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">CYBA</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">BAFF-R</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Gene mutated in Chediak-Higashi syndrome is?</span></p>",
      "unique_key": "DT1230101",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230101,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Chediak-Higashi Syndrome (CHS) </strong>is a rare autosomal recessive phagocytic disorder caused by a mutation in the LYST gene located on chromosome 1q42.1&ndash;q42.2.</p>\n<ul>\n<li>LYST (Lysosomal Trafficking Regulator) gene encodes a protein essential for proper vesicle trafficking and lysosome degranulation.</li>\n<li>Defective protein function results in:\n<ul>\n<li>Abnormal giant granules in neutrophils and other cells</li>\n<li>Impaired phagolysosomal fusion</li>\n<li>Defective neutrophil killing</li>\n</ul>\n</li>\n<li>Clinical features include partial oculocutaneous albinism, recurrent pyogenic infections, and accelerated hemophagocytic phase (HLH-like picture).<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240319ce53a61a-0fab-4835-9b65-4efed1f15f87.jpg\"></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>NCF1 (Option B): </strong>Encodes p47phox, defective in Chronic Granulomatous Disease (CGD)</p>\n<p><strong>CYBA (Option C): </strong>Encodes p22phox, another CGD-associated gene</p>\n<p><strong>BAFF-R (Option D): </strong>Mutation leads to Common Variable Immunodeficiency (CVID)</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>LYST gene mutations disrupt lysosomal trafficking in Chediak-Higashi Syndrome, causing immune and pigmentation defects.</p>",
      "correct_choice_id": 101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">X-linked agammaglobulinemia</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">IgG subclass deficiency</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Common variable immunodeficiency</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic graft-versus-host disease</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 10-month-old male infant presents with recurrent lobar pneumonia, the second episode in the last 3 months. Evaluation reveals markedly reduced levels of all immunoglobulins, absent tonsils and adenoids, and absence of peripheral blood B lymphocytes. What is the most likely underlying immunodeficiency?</span></p>",
      "unique_key": "DT1230130",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230130,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This clinical profile is classic for X-linked agammaglobulinemia (XLA):</p>\n<ul>\n<li>Occurs in male infants after 6 months of age when maternal antibodies wane</li>\n<li>Presents with recurrent bacterial infections (e.g., otitis, pneumonia, sinusitis)</li>\n<li>Caused by mutation in the BTK gene, leading to failure of B-cell maturation</li>\n<li>Lab findings:\n<ul>\n<li>Very low or absent IgG, IgA, IgM, IgE</li>\n<li>Absent circulating CD19+ B cells</li>\n<li>Absent or hypoplastic tonsils and lymphoid tissue</li>\n</ul>\n</li>\n</ul>\n<p><strong>Management:</strong></p>\n<ul>\n<li>Lifelong IVIG therapy to maintain protective IgG levels</li>\n<li>Aggressive infection treatment and pulmonary care (to prevent bronchiectasis)</li>\n<li>Genetic counseling for families (X-linked inheritance)</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>IgG subclass deficiency (Option B): </strong>Only one or more IgG subclasses reduced, usually presents with mild sinopulmonary infections; tonsils and B cells are present</p>\n<p><strong>Common variable immunodeficiency (Option C): </strong>Onset is later in life (after age 2-5 years or even adolescence). B cells are present, but fail to differentiate into plasma cells</p>\n<p><strong>Chronic GVHD (Option D): </strong>Seen in post-transplant patients; involves rash, diarrhea, liver dysfunction, and systemic immune suppression not isolated hypogammaglobulinemia in infants</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>XLA presents in male infants after 6 months with absent B cells, pan-hypogammaglobulinemia, and recurrent bacterial infections.</p>",
      "correct_choice_id": 111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3, 4</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3, 4</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 14-month-old child has steroid-dependent nephrotic syndrome. Look at the 4 statements mentioned below.<br>1. All live vaccines can be given<br>2. Killed vaccines can be safely given<br>3. Siblings should not be given OPV<br>4. The  Pneumococcal Vaccine should be given before commencing the treatment with steroids<br>Which of the following statements about the vaccination of this child is true?</span></p>",
      "unique_key": "DT1230195",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230195,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This child is immunosuppressed due to prolonged daily corticosteroid use. According to immunization guidelines:</p>\n<ul>\n<li>Killed vaccines can be safely given:\n<ul>\n<li>Inactivated vaccines (e.g., pneumococcal, DPT, IPV) are safe in immunosuppressed children.<strong> (Statement 2) </strong></li>\n</ul>\n</li>\n<li>Sibling should not be given OPV:\n<ul>\n<li>OPV is a live attenuated vaccine that can shed in stool and infect the immunocompromised child. Use IPV instead.<strong> (Statement 3) </strong></li>\n</ul>\n</li>\n<li>Pneumococcal vaccine should be given before starting immunosuppressants:\n<ul>\n<li>Ideally, vaccines should be given 2-4 weeks before starting immunosuppression to ensure optimal antibody response.<strong> (Statement 4) </strong></li>\n</ul>\n</li>\n<li>All live vaccines can be given:\n<ul>\n<li>Live vaccines are contraindicated if the child is receiving &ge;2 mg/kg/day or &ge;20 mg/day of prednisolone for &ge;14 days.</li>\n<li>They may be given after a 4-week steroid-free interval.<strong> (Statement 1)</strong></li>\n</ul>\n</li>\n</ul>\n<p><strong>Key Clinical Guidance:</strong></p>\n<ul>\n<li>Do not give live vaccines (e.g., MMR, varicella, OPV) to immunosuppressed children</li>\n<li>Killed/inactivated vaccines are safe but may require repeat dosing if immune response is suboptimal</li>\n<li>Ensure household contacts are vaccinated with safe alternatives (e.g., IPV instead of OPV)</li>\n</ul>\n<p><strong>Key Takeaway:</strong></p>\n<p>Children on long-term high-dose steroids should not receive live vaccines, but killed vaccines are safe, and household contacts should avoid transmissible live vaccines like OPV.</p>",
      "correct_choice_id": 122,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Risk of Guillain-Barr&eacute; Syndrome</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Risk of severe dengue infection</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Risk of toxic shock syndrome</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Risk of multiple sclerosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Dengvaxia is a globally licensed vaccine against Dengue, but is not available in India owing to concerns over a specific adverse effect. What is that adverse effect?</span></p>",
      "unique_key": "DT1230245",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230245,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Dengvaxia may increase the risk of severe dengue in <strong>seronegative individuals</strong> due to antibody-dependent enhancement (ADE).</p>\n<ul>\n<li><strong>Dengvaxia</strong> is a <strong>live attenuated recombinant tetravalent vaccine</strong>, based on a <strong>yellow fever virus (17D) backbone</strong> expressing the <strong>prM and E proteins</strong> of all four dengue virus serotypes (DEN-1 to DEN-4).</li>\n<li>It is approved in several endemic countries but <strong>not approved in India</strong> due to safety concerns.</li>\n<li>It is recommended only for children aged <strong>9-16 years</strong> with <strong>laboratory-confirmed prior dengue infection</strong>.</li>\n<li>In <strong>seronegative children</strong>, the vaccine mimics a silent primary infection. Later natural infection acts as a secondary infection, leading to severe dengue via <strong>antibody-dependent enhancement</strong>.</li>\n<li><strong>Schedule:</strong> 3 doses at 0, 6, and 12 months.</li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250907e94b35a0-8420-4402-9ba4-6b19bf467b91.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Guillain-Barr&eacute; Syndrome (Option A):</strong> Rarely linked to other vaccines (e.g., Influenza), not associated with Dengvaxia.</p>\n<p><strong>Toxic shock syndrome (Option C):</strong> Reported with <strong>reconstituted measles vaccine</strong> used beyond 4 hours, not Dengvaxia.</p>\n<p><strong>Multiple sclerosis (Option D):</strong> No evidence linking Dengvaxia to MS; more of a theoretical concern with certain older vaccines.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Dengvaxia is not used in India due to the risk of severe dengue in seronegative individuals caused by antibody-dependent enhancement.</p>",
      "correct_choice_id": 132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">X-linked agammaglobulinemia</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Chediak-Higashi syndrome</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Terminal complement C5b-C9 deficiency</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Human immunodeficiency virus infection</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A previously healthy 9-year-old girl is admitted for her second episode of meningococcemia in the past year. Blood cultures again isolate Neisseria meningitidis. She has normal growth and no history of other infections. Given the recurrence and pathogen specificity, which of the following is the most likely underlying immune defect?</span></p>",
      "unique_key": "DT1230079",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230079,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Recurrent infections with Neisseria meningitidis, especially in older children with otherwise normal immunity, strongly suggest terminal complement pathway deficiency (C5-C9).</p>\n<ul>\n<li>C5b-C9 components form the membrane attack complex (MAC), which lyses gram-negative bacteria by forming pores in their outer membrane.</li>\n<li>Deficiency of any MAC component leads to impaired killing of Neisseria, making the child vulnerable to recurrent meningococcemia or gonococcemia.</li>\n<li>These children are otherwise clinically well and often present late with pathogen-specific susceptibility.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>X-linked agammaglobulinemia (Option A): </strong>Presents in infancy with recurrent sinopulmonary and GI infections due to B-cell absence. No selective predilection for Neisseria; recurrent meningococcemia is not typical.</p>\n<p><strong>Chediak-Higashi syndrome (Option B): </strong>Characterized by partial albinism, giant cytoplasmic granules in neutrophils, and staph/strep infections. Caused by defective lysosomal trafficking not associated with Neisseria susceptibility.</p>\n<p><strong>HIV infection (Option D): </strong>Causes T-cell dysfunction, leading to viral, fungal, and opportunistic infections. Does not cause isolated Neisseria susceptibility; bacterial defense generally intact until advanced stages.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Recurrent Neisseria infections in a previously healthy child are classic for terminal complement (C5-C9) deficiency, due to failure of MAC formation and bacterial lysis.</p>",
      "correct_choice_id": 143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Bivalent OPV</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">BCG</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">MR</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Rotavirus</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All of the following vaccines are excluded from the Open Vial Policy except:</span></p>",
      "unique_key": "DT1230047",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230047,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The <strong>Open Vial Policy</strong> (OVP) under India&rsquo;s <strong>Universal Immunization Programme (UIP)</strong> permits the reuse of certain multi-dose vaccine vials for up to <strong>4 weeks</strong> after opening, <strong>provided strict conditions are met</strong>:</p>\n<ul>\n<li>Cold chain is maintained</li>\n<li>Vaccine vial monitor (VVM) is satisfactory</li>\n<li>Aseptic technique was used</li>\n<li>Expiry date has not passed</li>\n</ul>\n<p>Vaccines included under OVP:</p>\n<ul>\n<li><strong>Bivalent OPV (Oral Polio Vaccine)</strong></li>\n<li><strong>DPT, DT, TT</strong></li>\n<li><strong>Hepatitis B</strong></li>\n<li><strong>Pentavalent</strong></li>\n</ul>\n<p><strong>Vaccines excluded from OVP:</strong></p>\n<ul>\n<li><strong>BCG</strong> - reconstituted vaccine, must be used within 6 hours <strong>(Option B)</strong></li>\n<li><strong>MR (Measles-Rubella)</strong> - reconstituted, used within 4 hours <strong>(Option C)</strong></li>\n<li><strong>Rotavirus</strong> - comes as single-dose vial <strong>(Option D)</strong></li>\n<li><strong>JE (Japanese Encephalitis)</strong> - reconstituted, short shelf-life</li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<ul>\n<li>Open Vial Policy aims to reduce vaccine wastage while maintaining safety.</li>\n<li>It is applicable <strong>only to unopened and properly stored liquid vaccines in multi-dose vials</strong>, not to lyophilized (freeze-dried) or reconstituted vaccines.</li>\n<li>WHO and GoI have published specific guidelines governing this policy.</li>\n</ul>\n<p><strong>Key Takeaway:</strong></p>\n<p>Only selected <strong>liquid, multi-dose vaccines</strong> like <strong>bivalent OPV</strong> are allowed under the Open Vial Policy; <strong>reconstituted and single-dose vaccines</strong> are excluded.</p>",
      "correct_choice_id": 151,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Measles</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Polio</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Rotavirus</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral Typhoid</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Intussusception was a known complication of which of the following vaccines?</span></p>",
      "unique_key": "DT1230051",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230051,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Intussusception</strong> is a rare but recognized complication primarily associated with the <strong>first licensed rotavirus vaccine RotaShield</strong> (1998, USA), which was subsequently <strong>withdrawn from the market</strong> due to increased reports of this complication.</p>\n<ul>\n<li><strong>RotaShield</strong> was linked with a <strong>higher incidence of intussusception</strong>, especially <strong>within 1-2 weeks after the first dose</strong>.</li>\n<li>Later vaccines such as <strong>Rotarix</strong>, <strong>Rotateq</strong>, <strong>Rotavac</strong>, and <strong>Rotasiil</strong> were introduced with <strong>significantly reduced risk</strong>, particularly when the <strong>first dose is given before 12 weeks of age</strong>.</li>\n<li><strong>Rotavac</strong> is currently part of India's <strong>National Immunization Schedule (NIS)</strong>, given <strong>orally</strong> in <strong>3 doses at 6, 10, and 14 weeks</strong>.</li>\n<li><strong>Catch-up vaccination is not recommended beyond 1 year</strong> due to increased risk of intussusception in older infants.</li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<ul>\n<li>Intussusception typically presents with <strong>colicky abdominal pain</strong>, <strong>vomiting</strong>, and <strong>\"red currant jelly\" stool</strong> in infants.</li>\n<li>Despite the minor risk, WHO recommends rotavirus vaccines due to their major benefit in preventing severe diarrheal disease and deaths.</li>\n<li>Nelson emphasizes <strong>early scheduling</strong> of doses to minimize risk.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Measles (Option A):</strong> Live attenuated vaccine with no link to intussusception.</p>\n<p><strong>Polio (Option B):</strong> OPV is associated with VAPP (vaccine-associated paralytic poliomyelitis), <strong>not intussusception</strong>.</p>\n<p><strong>Oral Typhoid (Option D):</strong> Live attenuated Ty21a capsule; not associated with intussusception.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>The earliest rotavirus vaccine (RotaShield) was withdrawn due to its association with <strong>intussusception</strong>; newer vaccines like <strong>Rotavac</strong> are safer when given on time under the <strong>NIS</strong>.</p>",
      "correct_choice_id": 163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">MR Vaccine s.c. on left arm & Oral Vit A, at 9 months completed</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">MR Vaccine s.c. on right arm & Oral Vit A, at 9 months completed</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">MR Vaccine s.c. on left arm & Oral Vit A, at 8 months completed</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">MR Vaccine s.c. on right arm & Oral Vit A, at 8 months completed</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 9-month-old infant, previously vaccinated with BCG at birth and completed all immunizations till 14 weeks, now presents for routine follow-up. What vaccine(s) should be administered during this visit, and what is the appropriate route and site?</span></p>",
      "unique_key": "DT1230067",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230067,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>According to the <strong>National Immunization Schedule (NIS)</strong> under the <strong>Universal Immunization Programme (UIP)</strong> in India:</p>\n<ul>\n<li>The <strong>next scheduled visit</strong> after completing 6-10-14 week vaccines is at <strong>9 completed months of age</strong>.</li>\n<li>Vaccines administered at this visit include:\n<ul>\n<li><strong>MR (Measles-Rubella) vaccine</strong> - 0.5 mL <strong>subcutaneously</strong> on <strong>right upper arm</strong></li>\n<li><strong>Vitamin A (first dose)</strong> - <strong>1 lakh IU orally</strong></li>\n</ul>\n</li>\n<li><strong>JE vaccine</strong> (live attenuated SA-14-14-2) is additionally given in <strong>JE-endemic areas</strong>.</li>\n<li>As per <strong>2023 NIS update</strong>, a <strong>third fractional dose of IPV (0.1 mL intradermal)</strong> is also given at this visit.</li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<ul>\n<li>MR vaccine is given twice: at <strong>9 months</strong> and again at <strong>16-24 months</strong>.</li>\n<li>Vitamin A is given in a <strong>9-dose schedule</strong> starting at 9 months and continuing every 6 months until age 5.</li>\n<li>JE vaccine is region-specific (e.g., parts of Bihar, Assam, UP).</li>\n</ul>\n<p><strong>National Immunization Schedule Table (Updated 2023):</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090787e39900-8892-4bd9-a600-1c03c5095570.png\">\n<p><strong>Key Takeaway:</strong></p>\n<p>At 9 completed months, a child should receive <strong>MR vaccine (s.c., right upper arm)</strong> and <strong>Vitamin A (1 lakh IU orally)</strong>, as per India's <strong>Universal Immunization Schedule</strong>.</p>",
      "correct_choice_id": 172,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">BCG, DPT, MR, OPV</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">DPT, Rotavirus, OPV, MR</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Pentavalent, OPV, MR</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">DPT, OPV, MR</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An unvaccinated 13-month-old child comes to your clinic. What vaccines will be given at the 1st visit?</span></p>",
      "unique_key": "DT1230251",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230251,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>At age &gt;12 months, <strong>live vaccines like BCG and oral rotavirus, and primary series vaccines like pentavalent are not administered under catch-up policy</strong>-hence DPT, OPV, and MR are appropriate.</p>\n<ul>\n<li><strong>BCG</strong>: Given up to 1 year of age under NIS (unless special indication exists like TST-negative high-risk infants).</li>\n<li><strong>Pentavalent &amp; Rotavirus</strong>: Not given after 1 year due to reduced efficacy and increased risk (especially rotavirus).</li>\n<li><strong>At 13 months</strong>, permissible catch-up vaccines include:\n<ul>\n<li><strong>DPT</strong>: Safe and needed</li>\n<li><strong>OPV</strong>: Given in routine or catch-up</li>\n<li><strong>MR (Measles-Rubella)</strong>: Can be given until 5 years if missed</li>\n</ul>\n</li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250907138067ae-8948-4065-aaf7-4db382a5ee47.png\">\n<p><strong>Key Takeaway:</strong></p>\n<p>BCG, Rotavirus, and Pentavalent vaccines are not administered after 1 year under the national immunization schedule.</p>",
      "correct_choice_id": 184,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Haemophilus influenzae type b</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Influenza virus</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Tetanus</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Yellow Fever</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 4-year-old child with a history of mild asthma and recurrent wheezing is advised yearly vaccination with a vaccine that is not part of the National Immunization Schedule (NIS). Which of the following vaccines is being recommended?</span></p>",
      "unique_key": "DT1230083",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230083,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Annual vaccination is recommended against Influenza virus for children in high-risk categories, even though it is not part of India's Universal Immunization Programme (UIP/NIS).</p>\n<ul>\n<li>The vaccine currently available in India is an inactivated quadrivalent influenza vaccine.</li>\n<li>Recommended by IAP and WHO for high-risk individuals aged &ge;6 months.</li>\n<li>Not routinely given to all children, but essential in select medical conditions to reduce morbidity and complications.</li>\n</ul>\n<p><strong>High-risk groups eligible for annual influenza vaccination (as per IAP):</strong></p>\n<ul>\n<li>Chronic respiratory illnesses: Asthma, recurrent wheezing</li>\n<li>Cardiac, renal, hepatic, or hematologic disorders</li>\n<li>Immunodeficiency states (e.g., HIV, post-transplant)</li>\n<li>Metabolic disorders: Diabetes mellitus</li>\n<li>Sickle Cell Disease, SLE, and morbid obesity</li>\n<li>Children on long-term aspirin therapy (risk of Reye syndrome)</li>\n<li>Healthcare workers, lab personnel, and close contacts of immunocompromised patients</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Haemophilus influenzae type b (Option A):</strong> Part of routine NIS schedule at 6, 10, 14 weeks not annual</p>\n<p><strong>Tetanus (Option C): </strong>Given in DPT/Td booster format not annually</p>\n<p><strong>Yellow Fever (Option D):</strong> Only required for travel to endemic areas (Africa, South America); not used routinely in India</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Influenza vaccination is recommended annually in children with high-risk conditions, though it is not part of the National Immunization Schedule (NIS).</p>",
      "correct_choice_id": 192,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">The DPT full course should be repeated</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">Only DT needs to be given now</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">Give DPT 2nd dose</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">No need for DPT now</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A child reports to you at 1 year of age. He received DPT at 6 weeks of age but was lost to follow-up. What should be the next vaccination strategy regarding the DPT vaccine?</span></p>",
      "unique_key": "DT1230125",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230125,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>If a child misses scheduled doses, the immunization should resume from where it was interrupted.</p>\n<ul>\n<li>Repeating the entire series is unnecessary, even if there is a long interval.</li>\n<li>In this case, since the child received the first dose of DPT, the second dose should now be administered, followed by the third after 4 weeks and a booster at 16-24 months.</li>\n</ul>\n<p><strong>Maximum Allowable Ages (Per NIS/IAP):</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250907b685c4bc-6bf1-4350-9ba9-722892786539.png\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>The DPT full course should be repeated (Option A): </strong>Repeating full course is not needed</p>\n<p><strong>Only DT needs to be given now(Option B):</strong> DT is given for booster doses after 7 years, not in infants</p>\n<p><strong>No need for DPT now (Option D): </strong>DPT series is not complete, so next dose is essential</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>If an immunization schedule is interrupted, continue from where it was left, without restarting. DPT second dose is appropriate in this case.</p>",
      "correct_choice_id": 203,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">Give DPT</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">Give DT</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Avoid DPT in any form</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">Defer vaccination for 1 month</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 10-week-old child has come for vaccination. In the previous visit at 6 weeks, post-vaccination, the child had developed a fever of 40&deg;C and inconsolable crying for 1 hour. What next should be done?</span></p>",
      "unique_key": "DT1230248",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230248,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Fever of 40&deg;C and inconsolable crying for 1 hour are <em>precautionary events</em>, not contraindications, so <strong>DPT can be continued at 10 weeks</strong>.</p>\n<ul>\n<li>Events like <strong>high-grade fever</strong> or <strong>inconsolable crying</strong> after DPT are listed as <em>precautions</em> by IAP and WHO, not strict contraindications.</li>\n<li>Since the child had only one precautionary event, <strong>DPT is not stopped</strong> at this stage.</li>\n<li>If the same precaution recurs after the <strong>second dose</strong>, then DPT is replaced by <strong>DT</strong> at the 14-week visit.</li>\n<li>True <strong>contraindications</strong> include:\n<ul>\n<li>Anaphylaxis after previous dose</li>\n<li>Encephalopathy within 7 days of vaccination</li>\n<li>Progressive neurological disease (relative contraindication)</li>\n</ul>\n</li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250907a05b27a4-30d9-40db-a3ed-ee3297981e46.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Give DT (Option B):</strong> DT is used only <strong>after recurrence</strong> of precautionary events-not after a single episode.</p>\n<p><strong>Avoid DPT in any form (Option C):</strong> Not correct; contraindication criteria are not met.</p>\n<p><strong>Defer vaccination (Option D):</strong> No need to defer; child should receive vaccination on time.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Precautionary events like high fever or crying after DPT do not warrant stopping the vaccine continue DPT unless the same reaction occurs again.</p>",
      "correct_choice_id": 211,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">Live attenuated</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">Inactivated cell culture-derived</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">Inactivated Vero cell culture derived Kolar strain</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Japanese B Encephalitis Vaccine is recommended in the National Immunization Schedule in endemic areas. Which type of JE Vaccine is currently used in NIS?</span></p>",
      "unique_key": "DT1230247",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230247,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>JENVAC, the JE vaccine currently used in India&rsquo;s National Immunization Schedule, is an <strong>inactivated Vero cell culture-derived vaccine</strong> prepared from the <strong>Kolar strain</strong> (821564XY) of JE virus.</p>\n<ul>\n<li>JENVAC is a <strong>single-dose inactivated vaccine</strong> derived from <strong>Vero cell culture</strong>. <strong>(Option B ruled out)</strong></li>\n<li>It uses an Indian JE virus strain: <strong>Kolar strain 821564XY</strong>.</li>\n<li>Developed indigenously in collaboration with <strong>National Institute of Virology (NIV)</strong> and <strong>Bharat Biotech</strong>.</li>\n<li>Used for <strong>routine immunization</strong> in endemic districts of India under <strong>National Immunization Schedule (NIS)</strong>.</li>\n<li>It is <strong>not a live attenuated vaccine</strong> and differs from SA 14-14-2 (live attenuated) vaccine previously used. <strong>(Option A ruled out)</strong></li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250907f6d97e23-785f-4099-93f2-a9e8c3db590a.png\">\n<p><strong>Key Takeaway:</strong></p>\n<p>JENVAC, an inactivated Vero cell culture-derived vaccine using the Kolar strain, is the JE vaccine currently used in India's NIS.</p>",
      "correct_choice_id": 223,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24,
      "choices": [
        {
          "id": 231,
          "text": "<p><span style=\"font-size:12.0pt;\">Typhoid</span></p>"
        },
        {
          "id": 232,
          "text": "<p><span style=\"font-size:12.0pt;\">Td</span></p>"
        },
        {
          "id": 233,
          "text": "<p><span style=\"font-size:12.0pt;\">TT</span></p>"
        },
        {
          "id": 234,
          "text": "<p><span style=\"font-size:12.0pt;\">Chickenpox</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following vaccines do you recommend for a 10-year-old school child according to the national immunisation schedule?</span></p>",
      "unique_key": "DT1230201",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230201,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>As per the Universal Immunization Programme (UIP) of India, the Td (Tetanus and reduced Diphtheria toxoid) vaccine is recommended for adolescents at 10 and 16 years of age.</p>\n<ul>\n<li>Td has replaced the previously used TT vaccine, as diphtheria immunity wanes in adolescents and young adults.</li>\n<li>The Td booster helps maintain protection against both Tetanus and Diphtheria.</li>\n<li>The Td vaccine contains a reduced dose of diphtheria toxoid, which is better tolerated in older age groups<strong>.</strong></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Typhoid (Option A): </strong>Recommended by IAP and some state programs, but not part of the national schedule (NIS) for routine use at 10 years</p>\n<p><strong>TT (Option C): </strong>Previously used, now replaced by Td as per updated NIS</p>\n<p><strong>Chickenpox (Option D):</strong> Not part of NIS, though recommended by IAP after 1 year of age if not previously vaccinated</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>At 10 and 16 years of age, the Td vaccine is the only vaccine officially recommended under India's National Immunization Schedule.</p>",
      "correct_choice_id": 232,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 25,
      "choices": [
        {
          "id": 241,
          "text": "<p><span style=\"font-size:12.0pt;\">TT/Td</span></p>"
        },
        {
          "id": 242,
          "text": "<p><span style=\"font-size:12.0pt;\">Measles/MMR</span></p>"
        },
        {
          "id": 243,
          "text": "<p><span style=\"font-size:12.0pt;\">DPaT</span></p>"
        },
        {
          "id": 244,
          "text": "<p><span style=\"font-size:12.0pt;\">IPV</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A female child has had recurrent candidiasis and respiratory tract infections since the age of 3 months. She is now being evaluated for primary immunodeficiency. Which of the following vaccines is contraindicated in this child?</span></p>",
      "unique_key": "DT1230203",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230203,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>In children with suspected or confirmed B-cell and/or T-cell immunodeficiencies, live attenuated vaccines are contraindicated due to the risk of vaccine-induced disease.</p>\n<ul>\n<li>Measles/MMR is a live attenuated viral vaccine, and must not be given to children with cell-mediated immune defects, including Severe Combined Immunodeficiency (SCID) or DiGeorge syndrome.</li>\n<li>This child's history of recurrent candidiasis and RTIs from early infancy strongly suggests T-cell deficiency, which places her at risk for severe complications if given live vaccines.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>TT/Td (Option A): </strong>Toxoid (inactivated) vaccine, safe in all forms of immunodeficiency.</p>\n<p><strong>DPaT (Option C):</strong> Acellular pertussis formulation, considered a subunit vaccine, and safe in immunodeficient children.</p>\n<p><strong>IPV (Option D):</strong> Inactivated Polio Vaccine (IPV) is safe and preferred in immunodeficient children (unlike Oral Polio Vaccine, which is live).</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Live attenuated viral vaccines like MMR are contraindicated in T-cell and combined immunodeficiencies.</p>",
      "correct_choice_id": 242,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 26,
      "choices": [
        {
          "id": 251,
          "text": "<p><span style=\"font-size:12.0pt;\">MMR Vaccine before 9 months of age- Autism</span></p>"
        },
        {
          "id": 252,
          "text": "<p><span style=\"font-size:12.0pt;\">Reconstituted Measles Vaccine for more than 4 hours- Toxic Shock Syndrome</span></p>"
        },
        {
          "id": 253,
          "text": "<p><span style=\"font-size:12.0pt;\">Pneumococcal Conjugate Vaccine- Encephalopathy</span></p>"
        },
        {
          "id": 254,
          "text": "<p><span style=\"font-size:12.0pt;\">Varicella Vaccine- Axillary Lymphadenitis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which among the following is a correct match for the vaccine and the corresponding adverse event?</span></p>",
      "unique_key": "DT1230224",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230224,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Live reconstituted measles vaccine used beyond 4 hours increases the risk of <strong>Staphylococcus aureus-mediated Toxic Shock Syndrome</strong>.</p>\n<ul>\n<li>Live vaccines such as BCG and measles/MR must be used within <strong>4 hours</strong> of reconstitution; beyond this, the preservative efficacy is lost.</li>\n<li><strong>Toxic Shock Syndrome (TSS)</strong> is linked with use of contaminated vaccines due to <strong>S. aureus enterotoxins</strong>.</li>\n<li>Presentation of TSS: sudden fever, vomiting, hypotension, and possibly shock.</li>\n</ul>\n<p><strong>Related Important Points:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250907d0fd83a2-9b6b-46e7-8757-cceb1083c030.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>MMR Vaccine before 9 months of age - Autism (Option A):</strong> No scientific evidence links MMR to autism. Autism risk remains the same irrespective of vaccine.</p>\n<p><strong>Pneumococcal Conjugate Vaccine - Encephalopathy (Option C):</strong> No documented risk of encephalopathy; it is associated with whole-cell pertussis vaccine.</p>\n<p><strong>Varicella Vaccine - Axillary Lymphadenitis (Option D):</strong> Axillary lymphadenitis is more typical of <strong>BCG</strong>, not varicella.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Reconstituted measles vaccine must be discarded after 4 hours due to the risk of TSS caused by <strong>Staphylococcus aureus</strong>.</p>",
      "correct_choice_id": 252,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}